TABLE 2.
Results of lung function studies and nitric oxide (NO) gas exchange for visits 1 to 4 in asthmatic patients and healthy subjects
| Healthy subjects | Visit 1 F/S | Visit 2 F/S/M | Visit 3 S/M | Visit 4 S | |
|---|---|---|---|---|---|
| FVC (L) | 3.31±0.85 | 3.30±0.82 | 3.25±0.83 | 3.27±0.85 | |
| FVC (%pred) | 86±17 | 86±19 | 83±17 | 84±19 | |
| FEV1 (L) | 2.6±0.8 | 2.6±0.7 | 2.5±0.8 | 2.6±0.8 | |
| FEV1 (%pred) | 86±17 | 86±19 | 83±17 | 84±19 | |
| FEV1/FVC (%) | 77±10 | 78±9 | 77±10 | 77±10 | |
| FENO, 100 mL/s (ppb) | 12±5 | 16 (9–21) | 14 (9–21) | 15 (9–27) | 19 (10–32)* |
| CANO (ppb) | 3.2±2.0 | 3.6 (1.8–5.4) | 3.2 (1.8–5.5) | 2.8 (2.1–5.1) | 3.2 (2.1–5.2) |
| Airway NO (nL/s) | 0.85±0.55 | 1.0 (0.6–2.0) | 1.0 (0.6–1.8) | 1.7 (0.8–2.4) | 1.5 (0.7–2.6)** |
| Juniper score | 3.5 (1–8) | 2.5 (0–9) | 5 (2–12) | 7 (2–14)* |
Results for asthmatic patients are expressed as mean±SD and median (1–3 interquartile range). Results for healthy subjects are expressed as mean ± SD (1,7).
*
Visit 4 is different from visits 1 to 3, P<0.007;
**
Visit 4 is different from visits 1 and 2, P=0.03. %pred Percent predicted; CANO Alveolar NO concentration; F Fluticasone 250 μg twice a day; FENO fractional exhaled NO; FEV1 Forced expiratory volume in 1 s; FVC Forced vital capacity; M Montelukast 10 mg once a day; ppb Parts per billion; S Salmeterol 50 μg twice a day